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RESUMO 
 
 
O presente documento relata a minha experiência de 10 meses enquanto 
estagiária na Eurotrials, Consultores Científicos, uma Clinical Research 
Organization (CRO) portuguesa em expansão e, posteriormente, na Roche 
Farmacêutica Química, uma das indústrias farmacêuticas líder na área da 
saúde. 
Esta experiência, que decorreu entre Setembro de 2010 e Julho 2011, teve 
uma vertente multidisciplinar e monodisciplinar, o que me permitiu colocar 
em prática uma grande porção de conteúdos apreendidos nas disciplinas que 
compõem o Mestrado de Biomedicina Farmacêutica da Universidade de 
Aveiro, possibilitando a aquisição de variadas competências tanto a nível 
pessoal como profissional. 
Durante este período acompanhei inicialmente 9 ensaios clínicos como 
Clinical Research Associate (CRA) trainee e, progressivamente foi-me dada a 
oportunidade de realizar tarefas de forma mais autónoma e, 
consequentemente, de acompanhar 3 ensaios clínicos como CRA. Terminei o 
meu estágio curricular a desempenhar autonomamente todas as funções 
inerentes ao trabalho de um CRA. 
A elaboração deste relatório pretende descrever as atividades desenvolvidas 
ao longo de todo o estágio, bem como, dificuldades sentidas e aprendizagem 
consolidada. Para além disto, pretende também dar a conhecer a minha visão 
pessoal sobre o papel do CRA na condução de ensaios clínicos e os possíveis 
desafios a superar tendo em vista a continuidade de Ensaios Clínicos em 
Portugal. 
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ABSTRACT 
 
 
This document describes my 10-month experience as trainee at Eurotrials, 
Scientific Consultants, an expanded Portuguese Clinical Research 
Organization (CRO) and later at Roche Pharmaceuticals, a pharmaceutical 
industry leader in healthcare. 
 
This experience, which took place between September 2010 and July 2011, 
had a cross-disciplinary and mono-disciplinary strand, which allowed me to 
put into practice a great deal of content learned in the disciplines that make 
up the Master of Pharmaceutical Biomedicine, University of Aveiro, enabling 
the acquisition of several skills, both personally and professionally. 
During it was given me the opportunity to follow 9 clinical trials as Clinical 
Research Associate (CRA) trainee and gradually it was given me the 
opportunity to perform tasks more autonomously and hence to follow 3 
clinical trials as CRA. I have finished my curricular training being able to 
perform autonomously all tasks of the CRA job. 
 
The preparation of this report intends to describe the developed activities 
throughout the training, as well as encountered difficulties and consolidated 
knowledge. In addition, also intends to disclose my personal view on the role 
of CRA in the conduction of clinical trials and the possible challenges to 
overcome in order to continue clinical trials in Portugal. 
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1. INTRODUCTION 
This document reports the curricular training is part of the educational program of Master’s 
degree in Pharmaceutical Biomedicine and was passed in two institutions: Eurotrials, Consultores 
Científicos (Eurotrials), a Portuguese Contract Research Organization (CRO), and F. Hoffmann-La 
Roche Ltd. (Roche), a Swiss global health-care Company, on a pharmaceutical division. I initiated 
my curricular training on Eurotrials since September 6th 2010 to April 15th 2011. In February 2011 I 
accomplished Eurotrials requirements to be appointed as CRA. Since this promotion, I was able to 
work autonomously. 
Then, an opportunity arose to go to Roche, under Eurotrials responsibility, where I stayed from 
April 18th 2011 to July 06th 2011. 
In this report a characterization of the host institutions will initially be made. Then, the general 
training and specific activities, as well as the knowledge and experience acquired during my 
curricular training will be described. Furthermore, a discussion about my experience and 
encountered difficulties, as well as a brief comparative analysis, based on my ten-month 
experience, between working as CRA on a CRO (Eurotrials) and on a Pharmaceutical Industry 
(Roche) will be described. Finally, a conclusion about my whole experience will be presented. 
1.1. VISION ABOUT THE INSTITUTIONS – EUROTRIALS & ROCHE 
1.1.1. EUROTRIALS 
Eurotrials, Consultores Científicos, is a privately owned company founded in Lisbon in 1995 whose 
activities are focused on scientific consulting in the health area and clinical research (1). 
Eurotrials had a rapid and sustained growth and currently it operates in Europe, Latin America and 
Africa. This is, an office in Brazil was implemented since 2001 and it was started activities in some 
countries of Portuguese Speaking Africa in 2004 (1).Following this, in Figure 1 it is represented the 
overall structure of Eurotrials Portugal with ten main activities represented: Research & 
Development; Clinical Trials; Epidemiology & Late Phase Research; Data Management; 
Biostatistics; Regulatory Strategy & affairs; Pharmacovigilance; Quality and Teaching and Training 
(1). 
Currently, in Portugal it has a team of over 80 employees and includes physicians, biologists, 
pharmacists, biostatisticians, sociologists, nutritionists, chemists, engineers, psychologists and 
mathematicians, among others. In my opinion this is very worthwhile especially since many times 
this interdisciplinary allowed interesting brainstorms and also useful trainings carried out by 
employees who dominated a particular area. 
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Figure 1 - Organogram of Eurotrials Portugal (adapted from an internal Eurotrials’ presentation, 2011) 
The main services provided by Eurotrials are research methodology and consulting, study design 
elaboration, Protocol/ Case Report Form (CRF) development, implementation of clinical trials, 
project management, and monitoring activities (Phase I, II, III, and IV). It also grants data 
management and biostatistics, statistical and clinical reporting, epidemiological & late phase 
research, health economic studies; medical writing; quality assurance auditing and consulting; 
regulatory affairs; systematic review and meta-analysis; feasibility analysis and teaching and 
training (1). 
My curricular training was developed at Clinical Trials department under the direct supervision of 
a Clinical Trials Line Manager, Isabel Pinto, and Head of Clinical Trials, Raquel Reis.  In Figure 2 it is 
represented the organization of Clinical Trials department. The Head of Clinical Trials supervises 
four lines of clinical trials and each line usually has a Clinical Trial (CT) Line Manager, a Project 
Manager, a Lead Clinical Research Associate (CRA), a CRA, a CRA trainee and a Clinical Trial 
Assistant (CTA). 
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Figure 2 - Organogram of Eurotrials Clinical Trials Department (adapted from an internal Eurotrials’ presentation, 
2011). CRF – Case Report Form; CRA – Clinical Research Associate; CT – Clinical Trial; CTA – Clinical Trial Assistant. 
 
1.1.2. ROCHE 
F. Hoffmann-La Roche Ltd. Is a Swiss global health-care company that operates worldwide.  It was 
founded on 1896 in Basel (Swiss).  During the twentieth century the company grew and became a 
reference in pharmaceutical research, with an active presence in over 150 countries, including 
Portugal (2). 
Roche’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics.  
The company also owns the American biotechnology company Genentech and the Japanese 
biotechnology company Chugai Pharmaceuticals. The Figure 3 represents Roche divisions and 
subsequent acquisitions (3). 
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Figure 3 - General Structure of Roche (3) 
It is known that today, Roche supplies a wide range of diagnostic instruments and tests for 
disease detection and monitoring. In the therapeutic area, Roche has brought many effective 
drugs onto the market in the last few years. The main areas where Roche are focused include 
oncology, viral infections, metabolic and central nervous system disorders and inflammatory 
diseases. Oncologic drugs undoubtedly represent the majority of revenue for Roche (3).  
In Portugal, Roche started its activities in 1973; currently it has about 300 employees and is 
organized as presented in Figure 4 – Roche Diagnostics - and Figure 5 – Roche Pharmaceuticals. 
 
Figure 4 - Organogram of Portugal Roche Diagnostics (adapted from an internal Roche’s presentation, 2011) 
Roche Diagnostics, present in Portugal through Roche Sistemas de Diagnósticos, Lda., currently 
have 91 employees and operates throughout the country from the Roche offices in Amadora and 
Rio Tinto. Roche Sistemas de Diagnósticos, Lda. Is certified according with ISO 9001:2008 (2). 
Roche diagnostic division has an innovative role by cooperating with the Pharmaceutical division 
in the creation of tools for identifying effective therapies for complex health problems. Its main 
services are consulting and integrated solutions; clients assistance; commercial and financial 
services and regulatory affairs (2). 
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Figure 5 - Organogram of Portugal Roche Pharmaceuticals (adapted from an internal Roche’s presentation, 2011) 
The pharmaceutical sector, namely Roche Pharmaceuticals, is the largest of the group 
representing about 60% of total business (2). My curricular training was developed at this division, 
at Medical Direction department particularly at Clinical Operations under the supervision of the 
Clinical Operations Manager, Cristina Ventura. In Figure 6 - Organogram of Roche Medical 
Direction department (adapted from an internal Roche’s presentation, 2011)Figure 6 can be seen 
how Medical Direction department is divided, specifying the organization of the Clinical 
Operations department where I was included. 
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Figure 6 - Organogram of Roche Medical Direction department (adapted from an internal Roche’s presentation, 2011) 
1.2. STATE OF THE ART 
Clinical Research is defined as the research which is performed for patients, with interventions 
which are relevant to those and whose results are intended to serve as a basis for the diagnose 
decision, treat or make a prognosis of diseases that affect them (4). 
Clinical Trials are the universally accepted method for the investigation. These trials should be par 
excellence, randomized and controlled, to ensure the scientific validity of results (4). According to 
International Conference on Harmonisation – Good Clinical Practice (ICH-GCP), Clinical Trials are 
defined as “any investigation in human subjects intended to discover or verify the clinical, 
pharmacological and/or other pharmacodynamic effects of an investigational product(s), and/or 
to identify any adverse reactions to an investigational product(s), and/or to study absorption, 
distribution, metabolism, and excretion of an investigational product(s) with the object of 
ascertaining its safety and/or efficacy”(5). 
In addition to clinical trials, the observational epidemiological research is a key component of 
health research, which allows determining prevalence and incidence of certain diseases in the 
population, its characterization, quantification of the consumption of health resources, as well as 
the effectiveness and safety of drugs in the context of current clinical practice (4). 
Clinical Research has always been essential to the strategic development of pharmaceutical 
industry. However, this industry is constantly undergoing a change and it is verified that the 
concept of developing internally all this process and confine access to information or resources to 
third parties is becoming obsolete. In fact, in-house resources are getting exhausted with a very 
thin product pipeline and in addition many drugs are going off patent hampering company sales 
and increasing competitiveness. Generics market is growing fast and adding this to the low 
productivity of Research and Development (R&D) process and higher costs for product approval, 
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these are the major market feature for decreasing pharmaceutical profits. In other hand, global 
outsourced R&D is increasing every year leading to rise in business prospects for Contract 
Research and Manufacturing services (6). 
Outsourcing is being used more strategically as an ongoing part of a company’s overall business 
strategy. Outsourced activities can be in various fields from the drug discovery until the 
manufacturing of the products (6). 
CROs, defined on ICH-GCP as a person or organization (commercial, academic, or other) 
contracted by the sponsor to perform one or more of a sponsor’s trial-related duties and 
functions, first showed up in the biotech industry in the late 1970s and quickly took on a 
significant role in R&D, after expanding from drug discovery and preclinical work to clinical trials, 
drug manufacturing and even marketing (7). 
Outsourcing allows pharmaceutical companies to ramp up the R&D operations at a fast pace with 
minimal capital outlay. Some of the benefits of outsourcing are the reduction of overall costs; 
improvement of net earnings and cash flow; diversion of resources to focus on other skills such as 
marketing and minimization of investments in capital-intensive facilities (6). 
Currently, pharmaceutical companies and outsource partners work in symbiotic relationship 
where pharmaceutical companies provide their core competencies in marketing and 
commercialization and outsource partners supply new innovative products. To maintain this 
symbiotic relationship the outsourcing partners need to confidentially retain the proprietary 
knowledge and meet the regulatory compliance (6). 
Regardless of outsourcing agreements between pharmaceutical industry and CROs, clinical 
research always involves multiple sources of specific expertise from diverse areas, such as 
research and development, technical consulting, administrative and regulatory. 
As represented in Figure 7, there is a long and well defined process between the discovery of 
some molecules with essential characteristics to be a drug and the new drug ready to be on the 
market. This process may take 10 to 15 years and is divided in six main steps: 1) Laboratorial tests; 
2) Pre-clinical tests; 3) Clinical trials; 4) Authorities submission; 5) Approval and 6) Registry and 
Marketing (8).  
 
 
Figure 7 - Process of drug development, including estimated timelines (1) 
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The first step involves the identification of potential therapeutic targets resulting from research or 
medical needs unfilled. Numerous molecules are generated starting from chemical molecules 
manufactured and based on physic-chemical properties and pharmacological profiles desirable. 
These molecules will be evaluated for their ability to produce the desired effect in vitro and 
usually only a very small number of molecules reach the next stage which involves animal 
experimentation (pre-clinical studies). Extrapolation of the results obtained of pre-clinical studies 
in absence of evidence of potential toxicity allows exploratory tests phase and the first exposure 
in humans through clinical trials. These are carefully designed, conducted and controlled in 
accordance with consensual protocols to ensure compliance with high standards of safety, patient 
treatment, quality and interpretation of data (9). 
Clinical trials have evolved towards the harmonization of procedures, focusing on patient safety, 
with the consent of all participants - a common denominator in any trial. Currently, ethical issues 
and inherent risks in a clinical trial, as well as its impact on patients involved, are important issues 
that are carefully evaluated. This regulation was established based on documents as the 
Nuremberg Code and Helsinki Declaration which form the safety and ethical of participation of 
individuals in clinical trials. Nuremberg Code was developed on 1947 and establishes ten basic 
principles to protect participants in clinical trials (10). Helsinki Declaration was developed on 1964 
in order to establish ethical codes to physicians and to protect the clinical trials participants 
worldwide (11). ICH was created in 1990 in order to avoid existent differences on requirements to 
the drug development on the three pharmaceutical global markets: European Union, Japan and 
United States (12). On 1996 ICH-GCP guidelines were accepted in these three markets and it 
became the guideline to be followed on the development and conduction of clinical trials (13). 
Common Technical Document for the Registration of Pharmaceuticals for Human Use (CTD) was 
developed on 2000 and became the standard dossier used on Europe, Japan and United States to 
submit collected data from clinical trials to the applicable governmental authorities (14). On May 
2004, Directive 2001/20/EC became one legal document in the 25 member state of the European 
Community. This document establishes new requirements to the investigator and his clinical 
investigational teams to conduct non-commercial trials (15). 
Currently, Clinical Research in Portugal is regulated by Law 46/2004 of 19th August (transposed 
into National Law of Directive No 2001/20/EC of the parliament and Council of 4th April) (16) and 
Decree-Law No. 102/2007 of 2nd April (17), which together establish the legal regimen for the 
conduct of clinical trials with medicines for human use in Portugal. In addition, conducting a 
clinical trial depends on the approval/ prior opinion of three independent entities: National 
Authority of Medicines and Health Products (INFARMED); Ethics Committee for Clinical Research 
(CEIC) and National Committee for Data Protection (CNPD); and also on the Administration Boards 
approval of clinical trial contract (18). 
1.3. TRAINING OBJECTIVES 
The initial training plan included a cross-disciplinary experience that would allow passage 
through the various company departments, and a mono-disciplinary experience that would 
involve specialized preferred work. However, despite of being part of a curricular training 
process I was treated and recognized as belonging to a work team with responsibilities and 
duties equivalent to any independent training CRA. Additionally to my experience in Clinical 
Trials Department (the chosen option for the mono-disciplinary experience), I was also able to 
go through Biostatistics and Data Management departments (cross-disciplinary experience). 
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The main goals established for my curricular training were: 
 To understand the communication flow and inherent work in Clinical Trials department; 
 Understand how to organize the monitoring activity both from the point of view of a 
CRO as a Pharmaceutical Industry; 
 To be able to practice autonomously and efficiently the involved procedures in CT 
monitoring. 
 
The secondary goals were: 
 Meet the host companies, the other departments and the various activity ranges; 
 To apply theoretical knowledge acquired in the Biomedical Sciences degree and in the 
master’s course in Pharmaceutical Biomedicine, enabling a smooth relationship 
between the output of education and training systems and the contact with real work 
world; 
 Attend courses/ trainings that allow me to acquire new knowledge important to my 
professional practice; 
 Train the writing of technical documents; 
 To complement and enhance social and professional skills by attending training in a real 
work context; 
 Develop critical thinking in concrete situations in the clinical research area. 
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2. ON-THE-JOB TRAINING  
2.1. GENERIC TRAINING 
Once in Eurotrials, the opportunity to pass for some departments in order to understand how 
they work and interact with the other departments was given to me. The learned knowledge in 
the department of Data Management and Biostatistics will be described in the two following 
sections. 
2.1.1. DATA MANAGEMENT 
During my curricular training I had the opportunity to spend one day to understand how Data 
Management Department works, how the information flow is made and the interactions between 
this department and the others during all process of clinical research. Since it was only possible to 
spend one day in this Unit, it was decided to have theoretical approach about general procedures 
in order to acquire essential information to develop the activities as a CRA. 
For this, I could understand that this department in Eurotrials uses cutting-edge technology in 
electronic data collection and a validated data management system which is in strict compliance 
with FDA 21 CRF part 11. The new data-collection technologies include Web portals (to manage 
each project’s data), ePRO (electronic Patient Reported Outcomes, such as digital patient diaries 
by mobile phone or PDA, diagnostic and measuring devices with electronic data collection), 
Interactive Voice Response System (IVRS) and Interactive Web Response System (IWRS). 
In this department the Head of Data Management supervises the Senior Data Manager and has 
the collaboration of the Data Manager Quality Controller, Medical Reviewer and Case Report 
Form Developer. The Senior Data Manager in turns usually supervises Data Managers, Database 
Operators, Data Entry Operators and Information Technology Analyst and Developer. 
This department has participated in a large diversity of projects distributed for multiple areas, 
namely, Pneumology, Psychiatry, Vascular, Stomatology, Rheumatology, Nephrology, Medical 
Hydrological, Cardiology, Surgery, Endocrinology, Infections Diseases, Neurology, Oncology, 
Otorhinolaringology and others (Figure 8).  
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Figure 8 – Percentage of projects per scientific areas where Eutrotrials Data Management Department was involved 
until May 2011 (adapted from an internal Eurotrials’ presentation, 2011). 
Data Management is an essential element throughout a clinical trial. It can accompany the study 
from the beginning - CRF development - to the end - database standardization. 
Throughout the study there are two essential documents used as maintenance releases work:  
Protocol and CRF (either developed internally or not). 
 
 
Figure 9 - Information Flow in Eurotrials Data Management Department 
 The information flow in Eurotrials data management begins with the Database Development (as 
seen in Figure 9). However, sometimes the Data Management Department is contracted to 
develop CRF. In these cases, the CRF development precedes the database development. 
For a successful CRF development is very important to understand how the data will be collected 
and assure that parameters of the CRF are in compliance with study protocol. After being drawn 
up, it is sent to statistical department where it will be revised to ensure that all the required fields 
are present and in compliance with protocol.  
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After this, timelines are defined and the first document of the process is elaborated: Data 
Management Plan. This document includes important and formal information about how to 
handle data both during the research and after the project is completed, such as CRF completion 
guidelines, CRF tracking instructions, data entry guidelines, the data querying process and how 
corrections will be made. The goal of a Data Management Plan is to consider the many aspects of 
data management, data preservation, and analysis before the projects begins; this ensures that 
data are well managed in the present, and prepared for preservation in the future (19). 
Annotated CRF is the second important document to be elaborated even before the beginning of 
clinical trial.  An annotated CRF is a CRF in which the variable names are written next to the fields 
provided for the investigator. It serves as a link between the database/data sets and the questions 
on the CRF. The goal of Annotated CRF is to help both the programmer and the reviewer to 
understand the data sets since it defines variables, tables and how the fields will be noted. Thus, it 
is used from data entry step until the statistician (19). 
There is another document which has the same goal of Annotated CRF: Data Definition 
Documentation. This document consists of a Table of Contents and a collection of data 
description tables. The table of contents lists out all the data included in a submission and 
provides the location and information on each data domain. The data description tables describe 
the attributes and origins or derivation of all variables in each data domain. Basically, it is a 
technical print-out which is on Trial Master File of every study. However, it is not widely used by 
data managers due to its size (making it impractical) (20). 
The elaboration of these documents corresponds to the two first steps of database development 
– Planning and Requirements Gathering. After planning phase, the fields must be defined and 
tables created (Conceptual Design). Then it is necessary to create the logical design of application 
and database converted then to software systems that will be used to implement the database 
(Logical & Physical Design). Programming units are promoted to the system test environment, 
where the entire application and database is assembled and tested (Construction and Challenge). 
A functional report is generated by Quality controller and the Data Manager is responsible for 
correcting the findings. After the correction, database is approved by two team workers and is 
ready to receive data. Database Support Documentation is generated in the final of this process 
for each study and it is useful to train data entries.  
Commonly used methods to perform data entry are: “single key entry”, “double key entry” and 
“independent double key entry”. On a “single key entry” system, one person enters the data and 
another person print the results and compare with source documents.  On a “double key entry” 
one person enters the data and another person enters the same data into a mirror screen and the 
system compares the values in real-time. In this case, discrepancies are identified in the second 
they happen and they can be identified and if possible corrected immediately. The method of 
“Independent double key entry” is similar to “double key entry” with an exception regarding the 
second entry which is independently done and a program runs later to compare the two sets of 
entries. 
Data are entered and cleaned throughout the study. However, data quality activities must be 
conducted in order to eliminate potential errors that may distort the statistical analysis. To avoid 
this, all queries must be generated and resolved, and Data Validation Plan must be executed. Data 
Validation Plan defines what is made manually or on an automatic way. Currently in 90% of cases 
this validation is automatic, that is, there is software which is programmed to cross the 
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parameters which have to be crossed. In the other 10%, the data managers have to found 
manually discrepancies between the fields.  
After data validation, when a discrepancy is found, it is sent to solve for investigational sites. Sites 
have to solve within a limited period of time and so long as the discrepancy exist it will again be 
sent to site to be resolved. Data validation occurs only after discrepancy resolution. If discrepancy 
remains unresolved and there is no time to send more discrepancies to site, data manager has to 
report deviations and has to catalog the errors (with sponsor indication) in order to alert 
statistician to exclude data from deviations.  
When all issues are resolved, sponsor gives authorization to consider database “released” for 
analysis, i.e., locked. Data Set is send to statisticians and to provide a stable dataset for analysis, 
the database should not be changed after release, except in extreme cases and with sponsor 
authorization. 
In addition with dataset, randomization codes are sent to statistician in order to reveal which 
patients were on what treatment. This allows comparative analysis by treatment. 
The final step of data management process on the study culminates with Data Management 
Report which includes descriptive information about the study such as, number of patients who 
discontinued; screening failures and Adverse Events (AE) occurred.   
2.1.2. BIOSTATISTICS 
As happened in Data Management department, since it was only possible to spend one day in this 
unit, I should have theoretical approach about general procedures in order to acquire essential 
information to develop the activities as a CRA. 
The biostatistics department provides a wide range of services adapted to the needs of each 
project such as statistical advice and consultancy, study reports and assistance in preparing 
articles for biomedical journals. 
It also ensures correct methodological development and appropriate planning in clinical trials and 
guarantees the quality of protocols and reliable data processing, all of which are crucial to the 
success of any research project (1). This department has already a large experience on projects in 
many areas of clinical research as represented on chart below. 
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Figure 10 - Percentage of projects per scientific areas where Eutrotrials Biostatistics Department was involved until 
May 2011 (adapted from an internal Eurotrials’ presentation, 2011).  
Currently this department is constituted by a five elements team, namely, Head of Biostatistics, 
Senior Statistician, Senior Consultant, Statistician and Statistician Trainee.   
Biostatistics department collaborates with all departments in Eurotrials. In Figure 11 I have 
summarized the connections between biostatistics department and the other departments of 
Eurotrials; in particular, I would like to emphasize the link between this department and the 
department where I developed the specific training. 
 
 
Medical Hydrological 8% 
Cardiology 13% 
Surgery 3% 
Endocrinology 9% 
Pediatrics 3% 
Neurology 9% 
Oncology 16% 
Otorhinolaringology 4% 
Pneumology 9% 
Psychiatry 9% 
Vascular  3% 
Gastroenterology 3% 
Others 11% 
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Figure 11 - Biostatistics Department Interactions with other Eurotrials' departments (adapted from an internal 
Eurotrials’ presentation, 2011). 
Biostatisticians have an important role in the protocol development once they elaborate the 
methodology.  They also create randomization lists and Statistical Analysis Plan (SAP). This plan is 
a critical link between the conduct of the clinical trial and the Clinical Study Report (CSR). It 
defines the statistical analysis that will be performed for the clinical trial and all of the Statistical 
Analysis System (SAS) output required to be included in the CSR.  After data managers’ handover 
datasets to biostatistics department, as mentioned on the previous topic, biostatisticians have the 
responsibility to analyze the data and then to perform the statistical report. 
In the epidemiological studies there is no obligation to perform the SAP. Thus, in these studies the 
biostatistician performs a report only with a detailed statistical methodology.   
Biostatisticians have also an important role on the pharmacoeconomic studies which compares 
the value of one pharmaceutical drug or drug therapy to another. A pharmacoeconomic study 
evaluates the cost and effects of a pharmaceutical product. 
 In most clinical trials, economic data are not collected throughout the study. Even when they are, 
the data may need to be projected to populations, time periods, or settings that were not 
observed in the clinical study. In these cases, decision-analytic models may be used to generate 
some of the missing information. The data in a health economic model may be derived from 
various sources and is associated with varying degrees of uncertainty. Potential sources for the 
input variables in a model are clinical trials, literature, medical records, databases, expert panels, 
and official costs lists for resource utilization (21). 
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When a pharmacoeconomic study comes to biostatistics Eurotrials department if there is any 
defined method to perform the study, this is the first thing that biostatistician has to do. After 
this, a literature revision is made and a model is crated or reviewed, as applicable. Then, a 
questionnaire is made and an expert panel is selected to achieve a consensus. The expert panel is 
constituted by 5-7 physicians of the therapeutic area involved in the study and chosen by the 
sponsor. They cannot be from the same region or the same hospital from each other. There are 3 
methods to constitute an expert panel (22, 23): Delbecq method; Delphi method; and Key-
Informers method. The first one involves a face to face meeting with all experts, where the 
questionnaire parameters are discussed until reaching a consensus. The second one consists in 
sending the questionnaires by courier; the experts answer and send back to statisticians. A 
consensus questionnaire is made and sent again to experts to their approval. The last one consists 
on a personal interview to each expert (key-informer) in order to understand the different 
opinions about the subject in question. After all interviews made, a consensus questionnaire is 
made and sent to experts to their approval. Delbecq method is the most widely used because the 
estimates obtained by face to face consensus are more robust. After the expert judgment, costs 
calculation is made and inserted in the model. Then, the model is tested and a report is 
elaborated. 
Biostatisticians usually collaborate also with Regulatory Affairs department in the readability 
tests. These tests have as a fundamental goal to understand if patient information leaflet is on an 
accessible language and are easily understandable to the population in general. 
2.1.3. GENERAL TRAINING  
Throughout the curricular training I had the opportunity to attend various trainings that 
contributed to my professional development.  
I had to learn Standard Operating Procedures (SOP) both in ET and Roche. Additionally I had the 
opportunity to attend the following trainings: 
 “Observational research: the view of different stakeholders and the practical experience 
of conducting observational research”, by Maria João Salgado from Eurotrials, one hour 
training; 
 “Clinical research networks, are they in tune with sponsor’s needs?”, by Ana Filipa 
Bernardo from Eurotrials, one hour training; 
 “Planning and structuring investigational protocols”, by Luís Veloso from Eurotrials, one 
hour training; 
 “Time management”, by Graça Silveira from Eurotrials, one hour training; 
 “Study coordination in investigational site”, by Susana Bule from Eurotrials, five hours 
training; 
 “(In) security of information”, by Pedro Galvão from IBM, three hours training; 
 “Breast cancer”, by Hermínia Pereira  from Roche, four hours training; 
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 “Breast cancer – from diagnostics to treatment”, by Ida Negreiros from Roche, four hours 
training. 
All these trainings were very useful in that they facilitated the integration of important 
information used in the everyday practice and, in some cases, these helped to acquire more 
information about therapeutic area of projects in which I was involved. 
2.2. SPECIFIC TRAINING: CLINICAL TRIALS MONITORING 
Most of my training was spent in clinical trials monitoring, initially at Eurotrials and then, at 
Roche. 
According to ICH-GCP, monitoring is the act of overseeing the progress of a clinical trial, and of 
ensuring that it is conducted, recorded, and reported in accordance with the protocol, SOP, GCP, 
and the applicable regulatory requirement(s) (5). 
Trial monitoring intends to guarantee that the rights and well-being of human subjects are 
protected and that the reported trial data are accurate, complete, and verifiable from source 
documents (5). 
CRAs should be appointed by the sponsor, should be appropriately trained and should have the 
scientific and/or clinical knowledge needed to monitor the trial adequately. These qualifications 
should be documented. Despite this, CRAs should be thoroughly familiar with the investigational 
product(s), the protocol, written informed consent form and any other written information to be 
provided to subjects, the sponsor SOPs, Good Clinical Practice (GCP), and the applicable 
regulatory requirement(s) (5). 
Clinical trials monitoring requires that CRA in accordance with sponsor’ requirements, ensure that 
the trial is conducted and documented properly by carrying out the following activities when 
relevant and necessary to the trial and trial site: 
1. Acting  as the main line of communication between the sponsor and the investigator; 
2. Verifying that the investigator has adequate qualifications and resources, that facilities 
are adequate to safety and properly conduct the trial and remain adequate throughout 
the trial period; 
3. Verifying, for the investigational product, the storage times and conditions, the eligibility 
of patients to receive the investigational product, that information regarding properly 
using, handling, storing and returning were provided, controlled and documented and 
that the disposition of unused investigational product at the trial sites complies with 
applicable regulatory requirements and is in accordance with sponsor; 
4. Verifying that the investigator are adequately informed about the trial and follows the 
approved protocol and all approved amendment, if any; that written informed consent 
was obtained before each subject’s participation in the trial and that investigational staff 
team are performing the specified trial functions and have not delegated these to 
unauthorized individuals; 
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5. Ensuring that investigator receive current Investigator’s  Brochure, all essential document 
and trial supplies needed to conduct the trial properly; 
6. Verifying that the investigator is enrolling only eligible subjects and reporting the subject 
recruitment rate; 
7. Verifying the trial documentation, such as source documents, required submissions, 
applications, reports and CRFs, are accurate, complete, legible, dated and maintained; 
8. Determining if all adverse events are appropriately reported within the time periods 
required by GCP, the protocol, INFARMED, CEIC, the sponsor, and the applicable 
regulatory requirement (s). 
The CRA plays a major role in the successful conduct of a trial. Quality and trial results are directly 
influenced by CRA capabilities and the established relationship with investigator and study tem. 
The CRA must perform comprehensive site management and monitoring activities which include 
the following types of monitoring visits: 
1. Pre-study qualification visits (after the feasibility); 
2. Initiation visits; 
3. Interim monitoring visits; 
4. Close-out visits. 
All these activities must be performed in accordance with ICH-GCP (5) to ensure all investigational 
sites are compliant with applicable regulations and protocol requirements. The main CRA 
objective is to ensure timely subjects recruitment, patient rights, safety and data integrity. 
However, these tasks should be always accompanied with site management documentation and 
follow-up activities to ensure that site staff remains motivated and focused. Sometimes this 
motivation will falter over study, especially in long-term studies, which were going through 
several CRAs and constant changes in study team. In these cases is necessary a greater effort in 
order to motivate the team and ensure that they continue to enhance the study and its 
importance.  
In general, CRA should be able to balance characteristics as sensitivity, diplomacy, flexibility and 
kindness with firmness and precision to manage conflicts. 
Throughout my experience in clinical trials department I was given the opportunity to accompany 
experienced CRAs and to understand these mentioned aspects of being a CRA as well as the 
opportunity to perform almost all planned activities with the exception of study implementation 
activities and audits/inspections preparation tasks, due to the fact that during my training none of 
the studies where I was involved were in these two phases. Along the training I was able to 
perform activities in different studies and in different phases of clinical trial cycle, as represented 
in Table 1. 
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Table 1 – Description of Clinical Trials and activities where I was involved during my curricular training 
CT REF. 
NO. 
CLINICAL TRIAL DESCRIPTION 
ACTIVITY 
DEVELOPED 
1 Randomised three-arm multi-centre comparison of 1 year and 2 years of 
a treatment versus no treatment study in women with HER2-positive 
primary breast cancer who have completed adjuvant chemotherapy. 
Monitoring 
2 A single arm, multi-centre, international, continuation trial of a 
recombinant humanized antibody study in patients with HER2 
overexpressing tumors. 
Monitoring 
3 An open-Label randomized phase III study in patients who have 
undergone surgery for colon carcinoma, AJCC/UICC Stage III (Dukes Stage 
C). 
Close-Out 
4 Multicenter, double-blind, randomized, placebo-controlled, parallel 
group, prospective, event driven phase IV study on Pulmonary Arterial 
Hypertension.  
Monitoring 
5 Open-label, Uncontrolled, multicenter, Phase II study in patients with 
metastatic colorectal cancer. 
Monitoring 
6 Open, Randomized, Phase IV, multicenter Clinical Investigation in 
patients with Mild to Moderately Active Steroid Dependent Ulcerative 
Colitis. 
Monitoring 
7 Open-label, randomized, controlled, multicenter phase III study for 
subjects with advanced gastric adenocarcinoma of the gastro-esophageal 
junction. 
Monitoring 
8 Phase III, randomized, double-blind, placebo-controlled, multicenter 
clinical trial in subjects with a first clinical event at high risk of converting 
to Multiple Sclerosis. 
Monitoring 
9 A 2 year randomized, single-masked, multicenter, controlled phase IIIb 
trial in patients with macular edema and visual impairment secondary to 
Diabetes Mellitus.  
Initiation 
10 Phase III randomized trial to evaluate the efficacy and safety of second-
line therapy in patients with B-Cell Chronic Lymphocytic Leukemia.  
Monitoring 
11 Multicenter, randomised, double-blind, Phase III trial to investigate the 
efficacy and safety of therapy in patients with stage IIIB/IV or recurrent 
non-small cell lung cancer after failure of first line chemotherapy. 
Monitoring 
12 A multicenter, phase III randomized, double-blind, 3-Arm, placebo-
controlled, 78-week parallel group study to assess the efficacy and safety 
of the therapy in subjects with Mild to Moderate Alzheimer’s Disease. 
Feasibility 
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Having worked in various life stages of a clinical trial allowed me to understand the differences 
that each of these phases involve at time spent and type of work developed by CRA. In Table 2 
there is a schedule of activities developed in my specific training, accordingly with the main 
phases of the life cycle of CT. 
 
 
Table 2 - Schedule of activities during my curricular training 
X X X X X X X
X X X
X X X X X X
X X X X X
X X X X
X X X X
X X X
X X X
X X X X X X
X X X X X X X X X X X
X X X X
X
X X X X X X X
X X X X X X X X X X X
X X X
X X X X
X
X
X
X X
X X
X X
Close-out Visit (Preparation, execution and 
report)
Data Management and Database Close-out
Study documents translation
Drug accountability
Study Payments to sites
Substantial Amendement Submission 
Amendment Notification (CEIC, Principal 
Investigator)
Audit (Preparation, execution and follow-up)
Initiation Visit (Preparation, execution and 
report)
ICH/Legislation/SOPs
Protocol 
Informed Consent Form 
Case Report Form 
Trial Master File (Central File Archiving & 
Maintenance)
Developed Activities during the Training
SEP OUT NOV DEC MAR APR
ACTIVITIES
Feasibil ity Status to Sponsor
Feasibil ity Contacts
FEB
Newsletters
Monitoring Visits
In-house Monitoring (communication with 
Sponsor and sites, status reports, CRF revision 
and, management of queries, drug, supplies and 
documents, reports, follow-up letters and 
laboratory procedures)
Trial Master File (Central File Archiving & 
Maintenance)
Safety Information Notification (AEs/ 
ASR/SUSARs)
Investigator and Pharmacy Files
Trial Master File (Central File Archiving & 
Maintenance)
MAY JUN
Study Close-OutInvestigator and Pharmacy Files 
(Archiving and Maintenance)
Clinical Study Report
Feasibil ity VisitsFeasibility
Study Close-Out
Statistical Analysis 
Study Initiation
Study Specific 
Documents 
Familiarization
JUL
Study 
Monitoring
Investigator and Pharmacy Files (Archiving and 
Maintenance)
Study 
Implementation 
Submission to CNPD, CEIC and INFARMED
2010 2011
Pre-study Visits (Preparation, execution and 
report)
Site Contracts preparation
JAN
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I will now describe in more detail the planed and undertaken activities during my experience as 
CRA. I will focus more on the practical activity part since this experience had as main goal the 
consolidation of already acquired theoretical knowledge from masters’ degree. In Table 3 for the 
12 CTs where I was involved there is a description of therapeutic area, phase, type of 
randomization, blindness and comparator. 
 
Table 3 - Characterization of CTs where I was involved, including therapeutic area, type and study phase. All trials 
were international and multicentric. 
 
 
 
CT 
Ref. 
No. 
Therapeutic Area Phase Randomized Blind Comparator 
1 
Oncology 
(Breast Cancer) 
III  Open Label  
2 
Oncology 
(HER2 overexpressing tumors) 
IV Single arm Open Label Uncontrolled 
3 
Oncology 
(Colon Carcinoma) 
III   Open Label  
4 
Cardiology 
(Pulmonary Arterial 
Hypertension) 
IV 
 
 
Double-blind 
Placebo-
controlled 
5 
Oncology 
(Colorectal Cancer) 
II  Open Label Uncontrolled 
6 
Gastroenterology 
(Ulcerative Colitis) 
IV  Open Label  
7 
Oncology 
(Gastric adenocarcinoma) 
III  Open Label  
8 
Neurology 
(Multiple Sclerosis) 
III  Double-blind 
Placebo-
controlled 
9 
Ophthalmology 
(Macular Edema and Visual 
Impairment secondary to 
Diabetes Mellitus) 
IIIb  Single-Masked  
  10 
Haematology 
(B-Cell Chronic Lymphocytic 
Leukaemia) 
III  Double-blind  
11 
Oncology 
(Non-Small Cell Lung Cancer) 
III  Double-blind  
12 
Neurology 
(Mild to Moderate Alzheimer’s 
Disease) 
III   Double-blind 
Placebo-
controlled 
 
 
23 
 
The first phase of my experiment as CRA began with the reading and the acquisition/consolidation 
of theoretical knowledge from specific trainings, SOPs, guidelines, directives and laws applicable 
to the specific tasks inherent to CRA role. This initial reading was guided by Susana Bule in order 
to clarify possible doubts and assure that this knowledge was understood. 
In this phase, I realized that when CRA worked in a CRO, despite having to know the SOPs of the 
company, also have to learn about each client's specific SOPs. CRA can use internal SOPs, external 
SOPs or both, depending of each project and accordingly with established contract. 
2.2.1. FEASIBILITY  
In the course of my training there was the opportunity to do a feasibility study assessment in a 
neurology study. A properly designed and executed feasibility study can provide an overview of a 
clinical trial’s challenges and the strategies to eliminate risks before the study begins. 
My experience with feasibility process began when a list of possible sites was given to me. 
Accordingly with previous information and past experience, sponsor had already chosen some 
sites to study development in Portugal and sent a list of them to CRO. My first task was to 
complete that list with other potentially interested sites and correct some mistakes regarding 
sites that were already on the list. Then, after sponsor approval, sites were contacted in order to 
receive the first information about the study and to understand if investigators were interested in 
participate in the feasibility study assessment. During this phase establishing contact with 
investigator was not always easy and in some cases, it was impossible due to their unavailability 
or even their lack of interest. Beyond this, the same investigators accepted to participate in the 
trial and in these cases, were asked to sign a confidential agreement and to answer a 
questionnaire sent by e-mail from international team. During this process, several status 
information were sent between CRA and international team until all potential interested 
investigators answered the questionnaire and send it via e-mail. 
All this process seems easy. However, if we take into account the short timelines provided by the 
sponsors, the unavailability of investigators and hence the need to repeat the demand for 
answering online the questionnaire online, it is not always an easy and quick process. Beyond this, 
as this process is done online directly via international team to investigators, the CRA had a more 
passive role to play. However, it is the CRA who knows perfectly if sites usually are engaged with 
study tasks, if investigators usually demonstrate commitment and willingness to participate in the 
study and if sites have the real interest in participate in clinical trials. This often means that 
feasibilities are a very challenging part of a Clinical Trial. In this process it is already crucial to 
identify potential interested sites of non-interested sites. 
2.2.2.  INITIATION VISIT 
During my training I was given the opportunity to prepare and accompany all initiation visits with 
an experienced CRA. These were carried out in a study that involved patients with macular edema 
and visual impairment secondary to diabetes mellitus. 
The main goal of this phase is to remember the procedures, criteria and design of the study. 
Ideally, at this time the study team has already an idea about the study and knows what 
procedures must be followed (24). However, in practice not always is like that and some teams 
have no idea about criteria or specific procedures of the study.  In any case, after this visit study 
team and site must be prepared to include the first patient in the study. CRA has a crucial role at 
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this point, being responsible for training and clarifying all doubts as well as to promote  immersion 
in the study, intercommunication and mutual help between all members of site study team (24). 
Before initiation visit, it is always necessary to obtain all essential documents (also known as 
green-light documents), such as INFARMED authorization, CEIC and National Data Protection 
Authority approval, site Administration Board approval and signed Financial Agreement, ethics 
approval of National Coordinator and Investigators Curriculum Vitae. Depending of clinical trial 
type and sponsor procedures, there may be other documents that are required before the 
initiation visit. 
Even before the initiation visit, CRA confirmed the initiation visit with Principal Investigator (PI) 
and all study team in advance and sent a written initiation visit confirmation letter with agenda 
meeting. It is very important that this agenda contain a duration estimate of each topic to be 
discussed in order to allow study team to organize their work accordingly. Sometimes it is not 
possible to gather the whole team at the same time. In these cases, CRA has to do separate 
trainings according with the availability of each onsite team member.  
The preparation of the visit has included the following tasks: 
 All necessary documents and approvals to initiate the study were reviewed and it was 
confirmed that no document was missing; 
 All essential documents were prepared to take to site, namely last approved version of 
the protocol and amendments (if applicable) and Informed Consent Form, patient diaries, 
Serious Adverse Event (SAE) forms; Investigator Site File (ISF) and Pharmacy File (PhF) and 
other specific study material; 
 Presentation was prepared and reviewed as well as all material required for the 
presentation; 
 All documents and forms have to be properly filled at this time, such as, authorization log, 
site initiation visit log, acknowledgments of receipt of material delivered in site initiation 
visit and training records, were prepared. 
During the visit, I was given the opportunity to present one part of the required information of 
the study and together with the CRA who accompanied me, the following study information was 
reviewed and discussed: 
 GCP and study objectives; 
 Investigational Products information; 
 The protocol and all important details such as inclusion/exclusion criteria, study design 
procedures, timelines, recruitment and protocol violations; 
 Case Report Form; 
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 Informed Consent Form (ICF), AEs, laboratory and pharmacy procedures; 
 ISF and PhF contents. 
It is very important to guarantee that all doubts about study objectives and design, 
inclusion/exclusion criteria, informed consent form obtaining and adverse event report are 
resolved to everyone in the study team. In order to overpass problems of misunderstanding, CRA 
led to site other support documents as a separately and practical sheet with inclusion and 
exclusion criteria. 
In this study, I was fortunate to be able to participate in all initiation visits which occurred in 
several sites. With this, I have noticed that every site is different from another and that the CRA 
has to be flexible enough to adapt to all teams and situations that are so different from each 
other. In some sites was possible to meet with all study team and in this case there was no need 
to go to other department to do a separately training. In other sites, the presentation session was 
initially to investigators and study coordinator and on a day after it was to pharmacists. 
Sometimes, in these cases, the pharmacists and the investigators did not know each other and 
this can be a problem in the sense that in situations of medication non-compliance, information 
could not come easily to the investigator. So depending of the different sites CRA approach and 
following support to study implementation must be adapted so consistency may exist in every 
sites despite the sites variable “scenarios”. 
 After the visit, CRA completed the site initiation visit report which describes how the visit took 
place, participants, performed procedures, the issues raised by the study team and the actions 
taken or actions that should be made while following this visit. Currently, the report is made 
online directly in a sponsor platform. A follow-up letter was also sent to site in order to document 
all tasks and activities performed in the visit, pending actions and timelines for recruitment.  
2.2.3. MONITORING VISIT 
During my curricular training it was given me also the opportunity to accompany several 
monitoring visits in different clinical trials. Despite differences between the therapeutic areas, 
there are similarities in the preparation, on-site and post-visit procedures. 
The main objective of a monitoring visit is to oversee the progress of the clinical trial, ensuring 
that is conducted, recorded and reported in accordance with the protocol, SOPs, GCPs and 
applicable regulatory requirements.  
In general, there is a Clinical Monitoring Plan defined by the sponsor or project manager of the 
study which determines specific requirements and activities associated with the study, protocol 
and sponsor. This plan is very useful once it gives guidance regarding protocol and CRF 
interpretation, rules to fill CRF, number and interval of planned visits, importance level given to 
required activities developed in the monitoring visit, study procedures, study team contacts, 
guidance to know what should be reported and when. CRA organize the study work and site 
monitoring visits based on this plan. 
To prepare the site monitoring visits I had to follow some procedures which are transversal to all 
studies and that I am going to describe below: 
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 Schedule a visit with the investigator and site study team. This schedule usually involves a 
phone call to understand the investigator and site study team availability and then,  a 
letter or e-mail (depending of the study and study site team) should be sent with 
information on the issues to be addressed, the staff that is expected to attend and the 
time needed to conduct the on-site monitoring activities; 
 Review monitoring reports and follow-up letters from previous visits and other 
documents such as, correspondence with the site and phone contact reports, in order to 
check any missing documents, outstanding action, issues and queries that need to be 
addressed during the visit; 
 Send the written confirmation (usually by e-mail) of the visit date and the agenda.  The 
agenda should include all issues to be addressed in the visit (e.g. pending queries and 
clinical processes that will go to be reviewed in the visit).  This information should be 
submitted in advance to ensure that the clinical processes necessary for the review are 
available on the day we scheduled. 
 Review the situation of SAEs occurred at the site and last visits performed by the patients, 
to determine expected Source Data Verification (SDV) to be performed for each patient; 
 Review discrepancies that have arisen to site since last visit. These discrepancies should 
be reviewed before the monitoring visit in order to check what is asked by Data Manager 
(DM) on each request. In case of doubt DM should be contacted in order to confirm how 
the discrepancy should be clarified by the center. If the study is going through  a database 
lock is very important inform DM in advance that CRA will make a visit to the given site on 
any given day in order to allow them to send all pending issues and discrepancies raised 
to this site and, consequently, to allow that everything is solved until the deadline 
(according with timelines). 
 Review the new information to be provided to the investigator and study team about the 
study; 
 Review the status of trial supplies and study IMP as well as respective documentation to 
be provided to the site during the visit; 
 Review the list of issues to be discussed and reviewed at the investigational site as well as 
prepare essential documents to update ISF and PhF (e.g. Updated Investigator Brochures; 
correspondence between sponsor and site, CRA and site and with CEIC/INFARMED; 
acknowledgement of receipt of materials to the site and new documents sent by sponsor 
(newsletters, safety annual reports, etc.) 
During the site visit, the activities developed were: 
 Revision of ICFs; 
 Revision and Update of ISF and PhF; 
 Perform SDV accordingly Monitoring Plan agreed with sponsor and collect CRF pages, 
when applicable; 
 Review electronic source documents; 
 Review CRF (electronic or in paper) data and resolve any discrepancies, if existent; 
 Check if there were any deviations and/or protocol, SOPs, GCPs and other applicable 
regulatory requirements violations; 
 Check for all AEs occurred per patient; 
 Verify that  the receipt, use and return of trial supplies and investigational products were 
being controlled and documented by the study authorized personnel; 
 When local laboratories are used, ensure that laboratory quality certifications and 
reference ranges are valid and updated for the parameters required per protocol;  
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 When central laboratories are used, ensure that all samples are being sent and 
procedures are correctly followed and documented; 
 Verify that facilities and equipment remain in the required study conditions;  
 Verify any changes in the study team and train any new team member to be delegated by 
PI; 
 When necessary, other departments involved in the study should be visited (e.g. 
pharmacy and radiology) to ensure that the required study procedures are being followed 
accordingly in such locations. In the pharmacy case, it should be made accountability of 
medication, verification of storage condition (e.g. temperature and humidity) and expiry 
date, and verification of medication dispensing and return per patient. Beyond this, it 
should be ensured that the information about the compliance of each patient is sent to 
the investigator. In most cases, Investigational site and pharmacy are physically 
separated. However, information must be passed to the PI in order to know if patient is 
taking correctly the medication. CRA has to encourage this communication between the 
Investigator and pharmacy teams. In cases of blinded and unblinded CRAs, the unblinded 
CRA must inform the pharmacy about the importance of having communication about the 
study with the PI. 
 Sign and date Monitoring Visit Log 
 Verify essential study forms such as, authorization log (if there is any new study member 
on  site team) and patient identification log (to be filled ongoing with the identification 
with all patients included); 
 Confirmation the randomization codes integrity. 
Sometimes due lack of time, it was not possible to accomplish all these activities during a 
monitoring visit. In these cases, the priority was ICFs and the safety information verification. I 
think that these are the most important and essential aspects of the monitoring visit. Then, SDV 
was performed and CRF reviewed.  The rest can be made ongoing throughout the study. 
During my experience in the sites, I have noticed that ICFs are the most critical process and where 
sites often make mistakes, such as, errors in dates, signatures in the wrong fields and PI 
signature/date made before patient signature/date. In these cases, it was necessary to refresh PI 
about the information process of obtaining ICFs. 
Along my experience I have realized that although there are standard basic procedures to perform 
the monitoring visits, each study has different characteristics and in each one of them it is 
necessary to perform very specific procedures. In some of the studies that I have accompanied, I 
had paper CRFs and in the other I had electronic CRFs. In the studies where I have worked with 
paper CRFs, the original must be collected and sent to DM, a copy must be sent by fax to a 
sponsor/CRO platform and then keep it in the CRF. In the case of electronic CRFs, the procedure is 
totally automatic and there is no need to go to site to collect CRFs.   
After the visit a report must be performed. My reports were all made in sponsor platforms which 
eliminates the necessity of sending the report manually to sponsor. Also, a follow-up letter is 
always sent to site. 
Beyond monitoring visits, it is very important that CRA maintains a regular communication with 
sites in order to keep up to date on safety information, recruitment or other important 
information that may arise. This communication must be always documented. In some studies 
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there are Telephone Contacts Report sheets that must be filled for any contact made by 
telephone with the site teams. 
2.2.4. CLOSE-OUT VISIT 
During my curricular training I had the opportunity to prepare and execute a close-out visit. 
A close-out visit is prepared when (25): 
 The study is concluded, in accordance with Protocol; 
 The sponsor decided to interrupt the study in all investigational sites (as a result of a 
interim analysis) or in a single site (e.g. as a result of recruitment failure); 
 The Investigator, Ethics Committee, Administration Boards or Health Authorities may 
request the interruption of the study or the investigational site participation in the study. 
 
The close-out visit that I have prepared was made following the study completion in accordance 
with protocol, with also the sponsor authorization and the confirmation that no more data 
queries would be raised from data manager. In certain cases and upon sponsor request, the close-
out visit can be performed before database definitive lock. In these cases a declaration regarding 
the availability of the investigator to resolve queries after close-out visit should be obtained by 
the CRA. 
The first step was to schedule the close-out visit with the site team, and after that to prepare the 
site visit.  The preparation of this visit should follow the procedures used for any monitoring visit 
described above. Thus, in addition I have taken the following points into account: 
 Confirm in advance the meeting time and place, as well as, send a meeting agenda and a 
confirmation letter which should detail the aims of the site close-out visit and request all 
necessary trial  supplies and materials, including investigator file, to be available for the 
visit; 
 Arrange a visit to the departments also involved in the clinical study (e.g. pharmacy). I 
have experienced that not always the CRA can arrange these visits in the same day. In my 
case, due to holiday periods of the investigator and the pharmaceutical and, 
consequently due to unavailability for the same day, I had to do the site close-out visit on 
two different days. 
 The Trial Master File must be reviewed in-house to reconcile the documentation available 
and to identify any documentation that may have to be obtained from/or delivered to 
the investigational site; 
 The payments to investigational team should be reviewed in order to understand and 
assure that they were all already performed. 
 
As I mentioned above, the site close-out visit was performed in two different days. In the first day 
it was only possible to meet with investigator and study coordinator. Thus, as it was not possible 
to meet with pharmacist, it was decided with the sponsor that the first visit would be reported 
still as monitoring visit and then it would be schedule a formal close-out visit (when scheduled 
with pharmacist). 
Yet, on the first day of close-out visit, the following items were verified and discussed: 
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 ISF – All documents included in ISF were verified and it was ensured that all have been 
correctly completed and archived. Some documents must be updated and collected for 
the Trial Master File (TMF) and left copies in the ISF (e.g. Authorization Personnel Log and 
Site Visit Log). In other hand, there are others that must be in the ISF and copies must be 
provided for the TMF (e.g. Patient Screening & Enrolment Log). It should be noted that 
Patient Identification log is the only document that remains exclusively in the ISF. For 
missing documents, a note to file was generated in order to document the reason of its 
absence; 
 CRFs – All CRFs were verified in order to ensure that all filled CRF pages have been 
collected (in this case because it they were paper CRFs) and that investigator kept a full 
copy of each patient; 
 Queries – It was verified that all queries were resolved to date; 
 SAEs – It was verified that all SAEs have been reported properly identified, reported, 
notified and followed-up as much as possible by gathering the last information available 
in case there is any update information since last follow up; 
 Biological Samples – It was verified if all biological samples were shipped to central 
laboratory and if the records of sample shipping were completed and properly archived; 
 Patient Identification Log – It was verified if this form was completed  and archived in the 
ISF; 
 Storage of ISF, CRFs copies and source documents in a safe and restricted access place 
according with the period of retention defined; 
 Financial Disclosure Form – It was reminded that investigator is responsible to notify the 
sponsor if changes to the Financial Disclosure Form occur until one year after completion 
of the study as defined per protocol; 
 Audits and Clinical Study Report – It was discussed the possibility of an audit by the 
sponsor and/or inspection by Health Authorities after the site close-out visit and the 
necessity of include the Clinical Study Report in the ISF when it has been finished. 
 
In close-out visits, CRA should also ensure that any equipment provided to the site for the 
purpose of study conduction was returned on this visit. In this case due the longevity of the study, 
there was no equipment provided and, consequently, nothing to return. 
At the final of this visit all binders of ISF were clearly labelled with the following information: 
 Eudract  Number (if applicable); 
 Protocol Number; 
 Name of Sponsor; 
 Name of Investigator; 
 Investigational Site Identification; 
 Archiving End Date, in accordance with applicable legislation/sponsor (fifteen years, in 
this case). 
 
After this visit a site visit report was sent to sponsor (within 10 working days) and a follow-up 
letter was sent to investigator, where it was mentioned that the scheduling of the formal close-
out visit remained pending until it will be scheduled with pharmacist in order to review the PhF 
and IMP records.  
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After the scheduling of close-out visit with pharmacist, the formal close-out visit was performed 
and the PhF and IMP records were verified. The activities performed regarding the PhF were 
similar to the ones held during ISF revision, such as, verify if PhF was up to date with all 
documents correctly completed and properly archived and keep it archived together with 
Investigator File. In this case under pharmacist request, PhF was verified in pharmacy and after 
sealed, was transferred to the Investigational Site Department where ISF was archived. Thus, all 
study binders were kept together under the responsibility of investigator. In other cases, PhF is 
kept under the pharmacist’ responsibility and he/she is responsible for keeping the PhF in a safe 
and restricted access place until the end of the retention period. In these cases, CRA must ensure 
that PhF binder is clearly labelled with the same information described for the Investigator File 
binder. The location of the PhF, either archived under the responsibility of the investigator or the 
pharmacist should be clearly mentioned in the close-out visit report. 
Regarding IMP, it was verified if the Investigational Product Dispensing Log was completed and if 
there any missing pages for the TMF need to be retrieved. A final accountability and reconciliation 
of the entire quantity of IMP received on site, used, not returned and not dispensed was 
performed.  
After the formal close-out visit a site close-out visit report was performed and sent to sponsor 
also within 10 working days. A follow-up letter was sent to Investigator with the significant issues 
found during the visit and the required actions to be performed. The site close-out visit report 
was archived in the TMF. 
Beyond this, a letter was sent to the Regulatory Authorities and the applicable Ethics Committee 
in order to notify the completion of the clinical study. This letter was accompanied with the 
Declaration of End of Trial, which must be sent by international team and submitted to CEIC 
within 90 days since the date considered as the end of trial date, in this case this date was the last 
patient last visit.  
After all close-out visits performed, a notification must be sent to CEIC in order to inform that all 
sites are closed. 
2.2.5. OTHER ACTIVITIES 
In addition to the activities outlined above, in the CT monitoring there are other important 
activities carried out throughout the life cycle of the CT, namely, documents submission to 
competent authorities; archive and documentation management; and audits and inspections. 
 Documents submission to competent authorities 
As defined in Law nº 46/2004 of 19th August, a clinical trial can only be performed if there was a 
previous authorization from INFARMED and a favourable opinion from CEIC. It is also necessary 
an authorization from each of Administration Board of the sites and from CNPD. 
During my curricular training I had no opportunity to execute all the process of submitting a 
request for opinion/ authorization. However, I could help and accompany other monitors that 
have prepared these submissions which are a very complex and slow process. These submissions 
are associated with a previous recovery and organization of all essential documents which are 
required by the authorities to submit the study and are related with the clinical trial, the IMP and 
in particular with the sites and personnel. 
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Beyond this, I had the opportunity to perform a request for opinion of a non-substantial 
amendment to the ethics committee. In practice the process is very similar to what is done at the 
time of submission of clinical trial. The difference lies in having a much smaller amount of 
documentation involved and, in this case, I only have notified CEIC. 
Thus, all these submissions are oriented by the “Standards to be taken by applicants on the 
format and content of the request for an opinion from CEIC to conduct clinical trials with 
medicines for human use, notification/ request for amendment, notification of adverse events 
and declaration of end of trial”. This document is in compliance and meets the requirements of 
the Law no. 46/2004 of 19th August and the Directive 2005/28/EC of 8th April. It also describes the 
information that may arise during the clinical trial, which must be submitted to CEIC for review or 
knowledge (26): 
 New developments related to the trial conduction or IMP development, where they are 
likely to affect the participants’ safety; 
 Adverse reactions notifications; 
 Situations where the trial is suspended or prematurely terminated by the sponsor. If 
INFARMED suspend or prohibit the clinical trial, CEIC should be informed.  
 
Substantial amendments occur when there is relevant information that leads to change in the 
clinical trial conduction and may involve changes to the protocol or new information related to 
the scientific documentation that supports it. The amendments are substantial when associated 
with significant impact on the following (26): 
 Security or physical/psychic integrity of participants; 
 Scientific value of the trial; 
 Conduction or management of the trial; 
 Quality and/or safety of the IMP used in the trial. 
 
Substantial amendments must be notified to CEIC, INFARMED and, in some cases the CNPD (e.g. if 
new data needs to be collected it is necessary to also perform a submission to CNPD). In other 
hand, it is not mandatory to notify CEIC or INFARMED regarding non-substantial amendments, but 
the process should be available in the trial master file to consultation in case of audit and 
inspection. However, I have verified that the companies define as default procedure always notify 
CEIC and INFARMED of non-substantial amendments. These notifications not always are 
performed individually because they can be submitted along with other notifications and 
amendments as agreed with the sponsor. 
Sometimes sponsors’ definitions of substantial and non-substantial amendments are in conflict 
with national requirements. It is always necessary confirm if the sponsor and national authorities 
definitions are the same. The process of submission should begin only after this. Anyway, sponsor 
can only implement the amendments when CEIC gives its favourable opinion and INFARMED does 
not present any objection. 
As I mentioned above, I had the opportunity to perform a non-substantial amendment 
notification to CEIC. This amendment was regarding a new Investigator Brochure (IB) which in 
comparison with the previous one, presented a risk-benefit ratio that remained the same. As so, it 
was performed a submission package (paper and electronic) which consisted in a cover letter and 
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a copy to be stamped/signed and returned to company; and a CD-ROM with the new IB. It was 
also prepared an exact copy of the submission package to archive in TMF, including paper 
document and CD-ROM. 
According with Law no. 46/2004, for all requests for opinion/ authorization the reasoned opinion 
must be reported to the Ethics Committee, the applicant and the INFARMED, within 60 days of 
receipt of the request by the Ethics Committee and INFARMED. However, if INFARMED/CEIC ask 
the applicant for information or documents complementary to the request, the period referred 
stops until receipt of the information or documents requested. 
During my experience as CRA I have noticed that CEIC in most of the cases does not meet the 
deadline of 60 days and usually raises many issues that long delay the whole process in 
comparison with other countries. This can be a big concern in that it commits the conduction of 
clinical trials in Portugal. 
Since most of clinical trials are multinational with competitive recruitment, if the approval of the 
trial in Portugal exceeds the previewed time, the recruitment period is somewhat diminished 
when compared with the other countries. The consequence is that sometimes it is impossible to 
include all foreseen patients in such a short period of time and, in a long term, international 
teams may decide not to involve Portugal in further studies. 
There is an added difficulty after the release of the conditioned opinion/ approval from CEIC and 
INFARMED, which relates to the submission of financial contracts. This is because each institution 
has its own contract specific templates and different assessment and negotiation response times, 
making the process cumbersome further reducing the time of recruitment.  
Portugal should turn more competitive in CTs setting and in recruitment since it could be passed 
over by other countries. We already assist to the situation where Portugal is not, in general, 
considered within the first layer of Countries to be selected for Clinical Trials in many therapeutic 
areas (27). 
Another issue that I have verified and that can also delay the sites initiation and recruitment 
period is related with financial contracts. After favorable opinion/authorization of clinical trial by 
the Sites Administration Boards, the executed financial contracts of each site must be notified to 
CEIC and INFARMED. Following that CEIC will then release the formal favorable opinion for the 
initiation of each site. This final and formal approval is released on a site by site basis and 
dependent on each site Contract notification. 
 Archive and Documentation Management 
Along all clinical trials, numerous essential documents are generated in the study which allows 
assessing the trial conduction and the quality of generated information. These documents reflect 
compliance with GCP and with all regulatory requirements by the investigator, sponsor and CRA. 
Thus, it is essential to maintain this documentation updated on TMF, file that contains all the 
essential documents, before the study starts, during its driving and after its completion. 
The archiving of these documents on TMF is made in accordance with sponsor or CRO SOPs, when 
applicable and as initially agreed. TMF is usually in the sponsor facilities and the CRA is 
responsible for keeping this documentation updated. When studies are international, the 
documentation must be sent on a regular basis with a transfer form of documentation for a 
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central archive. There are cases that sponsor only require the submission of TMF at the end of the 
study. In case of local studies, TMF is kept in sponsor or CRO (if delegated) facilities and it is only 
necessary to archive and keep the TMF updated.  
Throughout my experience I have noticed that it is not always easy to keep the file well organized 
and updated, especially in long-term studies and where several handovers may have occurred. In 
these cases, when a revision is made it is usually found that there are documents that are missing 
and are often no longer available to be recovered.  For these cases, the only solution was to write 
a note to file documenting the situation and the reason why documents are missing.  
CRA has also the responsibility of sending all relevant and essential documentation to site. 
However, it is investigator’s responsibility to maintain and update the ISF. There are some 
documents that only exist in ISF and which are essential for the assessment and traceability of the 
study. For example, as mentioned before the “Identification Patient Log” is archived only in ISF 
and it is very important in that it is the only form which makes the connection between the 
patient real identity and the participant coded identification in the study. Along my experience I 
have found that many investigators (especially when there are no Study Coordinators) do not give 
due importance to the file and sometimes it is the CRA that takes on the role of keeping the file 
updated. 
 Audits and Inspections 
During my curricular training it was not given me the opportunity to participate in a preparation 
of an audit/inspection to a site. However, I could help other CRA in the revision of TMF in order to 
prepare it to an internal audit. The main idea that I have retained after this task is that an audit 
preparation should be performed since the beginning of the study. As I said in the topic before, it 
is crucial that CRA archive and control all essential documents on a regular basis.  
After the audit, I had access to audit report and all founded issues were discussed with my line 
manager. For me it was very important once it allowed brainstorming and review of some specific 
and important procedures that sometimes failed to be accomplished. 
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3. DISCUSSION 
In this topic I will do a description of my experience in terms of what I have done, the tasks that I 
could not perform and the competences/skills acquired during these 10 months. 
First I will resume the clinical areas and study phases where I was involved, and then I will 
describe the encountered difficulties and possible key-factors for success as CRA. 
According to my point of view and my experience I will also make a brief description of the main 
differences found as CRA in a CRO versus Pharmaceutical Industry, and finally in this topic I will 
give my opinion regarding the future of the clinical trials/ monitoring processes in Portugal. 
3.1. ABOUT MY EXPERIENCE
During my curricular training it became a fact that the knowledge acquired and capabilities 
developed (such as verbal and non-verbal communication skills; ability to develop activities in 
teamwork; and to find solutions on an autonomous way) in the Biomedical Sciences degree and in 
the Pharmaceutical Biomedicine master’s course, were very useful and essential to achieve the 
goals I had set. 
As CRA and also member of a company, the understanding of how the companies are organized, 
how each unit adds value to the business, the reading of SOPs and the trainings received were 
essential to feel like a team member who has a clear idea about what goals should be achieved, 
what are the difficulties and what are the profits. Thus, in each company that I have worked, I felt 
like a team member who is working for a common goal and under a common mission and values. 
I have started my activities in Eurotrials in the Clinical Trials department (mono-disciplinary 
experience) and as mentioned before, I have also had the opportunity to understand how 
Biostatistics and Data Management departments work (cross-disciplinary experience). Despite of 
this very brief cross-experience and based on a theoretical component, it was important to 
understand how information flow is made from/to these two departments and how they connect 
with the others of the company.  
During my experience in Eurotrials, there was the opportunity to go to work to the client under 
the outsourcing regimen. It was then that I started working at Roche. This allowed me to meet a 
different perspective on the CRA work in the pharmaceutical industry and recognize the 
differences.  
Regarding my mono-disciplinary experience, as CRA I was involved in 12 clinical trials in several 
areas and in different phases. For me it was extremely rewarding and motivating to work in 
clinical areas as diverse. I have realized that although all therapeutic areas require much effort of 
a CRA, there are some that are generally more cumbersome to CRA/site team, in particular, the 
oncology which has almost always a lot more parameters and criteria to control and monitor in 
comparison with other pathologies. Therefore, I feel that I was fortunate to have worked mainly 
in oncology, since it prepared me to work in other easier areas. 
Although I have not worked in a Phase 1 study during my training, I have had the opportunity to 
see other CRAs working and I have concluded that these kind of studies usually are conducted by 
more experienced CRAs once they focus mainly on safety and tolerance to the drug and are the 
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first contact of IMP with humans. A constant observation of the participants must be done during 
this phase in order to accompany all signs and symptoms derived from the low doses of IMP given 
in a small number of people. The participants of these trials are usually healthy, although for 
some drugs, the first experiments in humans are made in patients with the disease that the drug 
is intended to treat. The dose of the new drug is gradually increased during the first phase to 
allow the researcher to measure the participant's clinical response to the drug, if the drug is 
sufficiently absorbed, how long the drug remains in the bloodstream after the administration and 
what dose levels are tolerable and safety (18).  
Beyond this, throughout my training I had the opportunity to develop the different activities 
inherent to the phases of a clinical trial life cycle (Feasibility, Initiation, Monitoring and Close-Out). 
As previously presented, I did not perform activities in the study qualification phase. However, I 
could understand that the qualification visit is not always performed due to low budget. In these 
cases, the initiation comes just after the feasibility. This can translate into problems of poor site 
selection since, at this time the feasibility process is done through surveys which go directly to 
sites and do not always reflect the reality of them. The CRA, someone who in fact knows how the 
site really is and how the teams usually work has more than ever a passive role in this process. 
Sometimes, in cases where there are no qualification’ visits, some sites are selected and actually 
do not meet all the conditions to insure a satisfactory clinical trial conduction and commitment.  
Along my training I have realized that although CRA can work in several clinical areas, with 
different study phases and with different teams, there are some aspects that does not change and 
which are transversal to all studies, in particular, the strong regulatory burden which began since 
the study conception, implementation, and development until the conclusion of the studies. The 
main objective of this regulatory burden is to ensure the protection and welfare of participants 
and maintaining the integrity of scientific results. 
In addition, I have noticed that CRA's role and responsibilities extend beyond those defined by the 
ICH-GCP and regulatory requirements. The diversity of functions that the CRA performs forces to 
adopt a pragmatic method of working, organized and responsible where the supervision of clinical 
trial must be balanced with the relationship and trust established with the study and site team. 
CRA's time is divided between the office and sites and a good CRA must be someone who knows 
how to work in a team and must have good interpersonal skills, such as good communication, 
flexibility and assertiveness. Throughout my training I had the opportunity to work with sites with 
a very good organization (infra-structure and human resources) and the opposite. This allowed 
me to conclude that a structured, experienced, trained and motivated team is able to conduct the 
clinical trial more easily in compliance with protocol and all legal requirements. It also allows me 
to conclude that in sites where a clinical research culture is implemented, the study site members 
are more enhanced with the study and the objectives are achieved with low time-consumed and 
less CRA effort. I have also verified that when a long time as passed since the beginning and the 
study becomes old, the study team loses motivation and commitment decreases. In these cases, 
despite of all characteristics mentioned before, CRA has to be creative and try to motivate the site 
team.    
In addition to this, the CRA must make a constant update on knowledge and training in order to 
be prepared for the different scientific areas and procedures which will have to deal with in 
professional life. Fortunately I was able to attend numerous training and courses which helped me 
to consolidate the knowledge acquired during the degree and masters’ course.  
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It is important to clarify that the opportunity I was given in Eurotrials and Roche as CRA allowed 
me contact with two very structured environments and with a very-well organized procedures. 
Therefore, along my training I had no opportunity to contribute to major improvements because 
both host companies have a vast experience. Despite this, as I became autonomous, I was able to 
manage my work independently and anticipate and prevent problems, for example, choosing to 
make additional visits to the sites. 
3.2. ENCOUNTERED DIFFICULTIES AND KEY-FACTORS FOR SUCCESS 
Along my curricular training I could prove that the acquired theoretical background that I have 
acquired previously, although extremely useful in the development of all tasks, does not give a 
real idea of what will be the actual business practice and the real working environment.  
During my experience in accompanying other CRAs in various tasks, I have realized that each one 
has a very different way of working and organizing, and quickly I realized that I would have to find 
a way of working that suited me best. Although it seems a detail, how the CRA organizes the work 
and information is extremely important since, as mentioned earlier, in this area there is always a 
lot of essential documents being generated, many parameters to control and lots of information 
to monitoring. A good organization of all information and well-established procedures are the 
basis for the CRAs' success. 
During my experience I always started to work in clinical trials which had already been monitored 
by another CRA(s). This can be a very challenging situation because despite of having always a 
handover meeting, there are issues that are not passed to the new CRA due lack of time or 
forgetting. Thus, the new CRA sometimes is surprised by problems that already existed but were 
not documented. This problem is increased when the studies are long-term studies and have 
passed by many CRAs. For me, it was very important to carry out handover visits and in some 
cases one visit would not be enough to have an idea about the real site status. In these cases, a 
second visit should be made.  In all cases, I think that is very important to document all issues and 
pending problems of the sites, being aware that the handover well accomplished is a key-factor 
for success of monitoring and, consequently, of clinical trial.  
The real lack of time of some investigators for clinical trials in which they are involved usually 
results in delays and minor mistakes in conduction of the study, for example, filing documents 
incorrectly or with a large delay.  It is very difficult to develop activities with a site team who has 
never time to the study and who is almost always unavailable to resolve study issues. In these 
cases, the CRA has to be patient but active in order to resolve the situation, either by motivating 
the investigator for the study or advising the inclusion of someone in the team that actually has 
time to study and to whom he can delegate tasks.  
In general, there are several essential characteristics that site should present: 
 There must be time and availability; 
 Teamwork; 
 Training; 
 Experience; 
 Patients;  
 Logistics. 
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Beyond this, it is known that clinical trials depends essential of multivariate conditions, so CRA 
must be aware about key factors to achieve the best conducting a clinical trial and give more 
importance to them, as well as, critical study phases/aspects like feasibility, recruitment, 
investigational team and accompaniment by CRA/ sponsor to site team. 
3.3. PHARMACEUTICAL INDUSTRY VS CRO: MAIN DIFFERENCES ABOUT BEING A CRA  
Fortunately during the curricular training I had the opportunity to develop activities as monitor 
through two different perspectives: CRA in a CRO (Eurotrials) and CRA in a pharmaceutical 
industry (Roche). I will describe below the main encountered differences. 
The reality provided by the training in a CRO as Eurotrials showed to be an asset in the acquisition 
of knowledge and practical skills for my professional development as competent and interested in 
monitoring clinical trials. In providing services to different sponsors, each one with its specific 
methods and procedures of work, Eurotrials gave me the opportunity to participate in different 
trials in different phases of development. This variety of phases, studies, clinical areas and 
methodologies promoted a growing knowledge and a rapid improvement on my technical, 
scientific and personal skills. 
The experience at Roche was also the enhancement of personal and professional level. Although I 
have been undergoing trials in follow-up phase which the tasks flow was decreased, on the other 
hand, I won autonomy at Roche. I began to manage my tasks more autonomously and to carry out 
monitoring visits alone. 
Regarding monitoring visits, it was the point where I noticed the most difference. The frequency 
of monitoring visits in CROs is determined for each study with the sponsor and defined in the 
study contract between sponsor and CRO, and in line with Clinical Monitoring Plan. However, the 
frequency for a specific investigational site could depend on the patient enrolment rate and site 
performance. Therefore, the CRA should discuss with Project Manager and/or sponsor, as 
appropriate, the adequacy of the monitoring visits frequency during the study contact 
progression. However, sometimes in international studies, the international study team is not 
within the reality of the Portuguese research sites, and compares Portugal to other developed 
countries with a more elevated level of conducting clinical trials. Thus, I found that they cannot 
always understand why CRA have to make an additional visit, when it is real necessary. I found 
that this is an advantage of working directly on the sponsor, since the people who approve the 
visits are directly working with CRA and knows very well the reality of the Portuguese sites and 
hence the need to  allow for an additional visit. 
Another difference found is that the CRA in the pharmaceutical industry often has access to the 
practical rationale that is behind the development of the study. For example, there are some 
patients who responded very well along many years to a medicine in a complex pathology and 
they will stop to take it just because the study where they were included will end. The 
pharmaceutical industry has the possibility to make an extension study that enables this group of 
patients who would have to stop taking medication have the possibility to continue to take it. In 
these cases the CRA can help identifying these patients in Portugal and help to identify the real 
benefit of these trials. 
Other aspect that is very different for the CRA who is working in a pharmaceutical company is that, 
as opposed to a CRO, there is a marketing department which sometimes has indirect influence on 
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how the sites are strategically chosen to clinical trials. This means that the sites are chosen by 
clinical trials by the medical department, fully independent of the marketing department. Yet, this 
later department eventually add some pressure to choose or maintain certain sites accordingly 
their marketing strategies. Thus, sometimes unfair situations can arise in the sense that not all 
sites where a large quantity of drugs is sold are good in the conduction of CT; and in practical 
terms, this situation can only lead to an extra effort by the CRA in order to ensure a good CT 
conduction, even if the site does not cooperate as it should and as initially planned.  
3.4. MONITORING: VISION ABOUT THE FUTURE 
Clinical Trials in Portugal are facing some challenges. The regulatory demands have been 
increased, other countries offer better conditions to run clinical trials, there is a decrease of 
innovative drugs, and clinical trials demand more resources (28). According to these facts, there is 
a high probability of clinical trials diminishing in Portugal (29). 
My experience has shown that in fact there are many gaps and challenges in clinical research in 
Portugal which must be overcome. It is verified that early clinical trials are not usually performed 
in Portugal, while phase III trials are the most performed. This is directly related with the fact that 
the majority of clinical trials performed in Portugal are funded by pharmaceutical industries and 
very few funded by academic institutions. This means that probably most R&D developed in these 
institutions is not translated into clinical research. 
Beyond this, as opposed to other countries, the hospitals do not usually show clear policies, 
motivation, interest and autonomy in carrying out the clinical trials. In addition, they have a 
lengthy and complex bureaucratic process of approval which has not standardized procedures 
and are not equal for all hospitals. As I could verify, a submission process to an Administration 
Boards can take months to be dispatched. 
Clinical trials bring many advantages for any country. Because of them, many patients have the 
opportunity to be treated with innovative drugs before their marketing authorization; the 
investigators have the opportunity in advance to improve their knowledge regarding new 
treatments, their benefits and risks; they also offer the opportunity to hospitals to use new 
technologies and know-how. For this and many other advantages, Portugal has to change. 
It has been already observed a pressure of international headquarters of pharmaceutical 
companies in order to align the procedures between countries, so that clinical trials in all 
countries could be successful and well conducted. Thus, some procedures have already been 
changed and implemented. For example, I have found that there is already an effort by some 
pharmaceutical companies in order to make the sites to get used to being more autonomous.  
Thus, the monitoring visits tend to be reduced, the SDV partially made and e-learning trainings 
will be the standard way to give and improve knowledge. Thus, the CRA will have more time to be 
in the office and carry out only his/her tasks, on a continuous and closer basis. This intends to 
make the study well underway since the beginning, where all the people involved actually 
perform the tasks according to their responsibilities. In my opinion, with this concept hospitals 
will need to have a better organized study team and for investigators that really do not have time 
to conduct the study, a study coordinator will be crucial. Also, the concept of close-out visits face-
to-face tends to be no longer applicable. In fact, if the study is well conducted from the beginning, 
all documents are reconciled and all issues are resolved in a continuous basis along the study. So, 
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many objectives of the close-out visit can be solved with continuous CT monitoring and this visit 
loses impact on the study in relation to what it has now.  
Although initially going to be difficult to implement these changes, I think that in a long term they 
will benefit all. However, it is important that sponsors take already action, for example giving 
training and clarifying hospital administration boards and investigators in order to incentive the 
clinical research in Portugal. 
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4. CONCLUSIONS 
This ten-month experience in Eurotrials and Roche proved to be a very enriching experience and 
extremely important in my continuous improvement and enhancement of my skills. 
I have realized that my degree and master’s course have given me a multidisciplinary background 
which allows me to perform the activities with some additional training. Thus, I think that 
Biomedical Sciences degree and the Pharmaceutical Biomedicine master’s course allows me to 
work in any one of the areas carried out in the clinical research. Despite not having gone through 
all departments, I think the original purpose has been fulfilled in the sense that I could see what is 
done in each unit and how it is done. 
Regarding the mono-disciplinary training, all developed work in the office or at the sites allowed 
me to understand this profession in practical terms, as well as the skills that a CRA should have. 
During this training, it was given me the opportunity to follow 9 clinical trials as Clinical Research 
Associate (CRA) trainee and gradually it was given me the opportunity to perform tasks more 
autonomously and hence to follow 3 clinical trials as CRA. 
For this, I think that my initial objectives have been achieved. 
After all this experience, I felt prepared to ingress in the working world and I really appreciated 
what I have done. My future objectives are the continuing acquirement of knowledge and 
improvement of my skills in order to be able to evolve and carry out any work of my interest. 
I would like to point out that this whole experience was so successful largely because of the 
people who I have been involved throughout my learning path. Again I thank to the entire 
Eurotrials team the tenderness, support and understanding at all times, from the beginning; also 
to the entire clinical operations team of Roche, where I grew up and acquired a new vision of 
being a CRA.    
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